-
公开(公告)号:US08501175B2
公开(公告)日:2013-08-06
申请号:US13124603
申请日:2008-11-10
申请人: Young Woo Park , So-Young Choi , Young-Soon Jang , Ji Hyun Park , Eun-Jung Song , Jung Yu , Myung-Ho Sohn , Jae Won Jeon , Joon-Goo Jung , Sungsub Kim , Myeoung Hee Jang
发明人: Young Woo Park , So-Young Choi , Young-Soon Jang , Ji Hyun Park , Eun-Jung Song , Jung Yu , Myung-Ho Sohn , Jae Won Jeon , Joon-Goo Jung , Sungsub Kim , Myeoung Hee Jang
IPC分类号: C07K16/00
CPC分类号: C07K16/40 , A61K2039/505 , C07K2317/21 , C07K2317/52 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C12N9/6424
摘要: The present invention relates to a transmembrane protease, serine (TMPRSS4)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to TMPRSS4. The TMPRSS4-specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.
摘要翻译: 本发明涉及跨膜蛋白酶,丝氨酸(TMPRSS4) - 特异性人抗体,更具体地涉及包含衍生自特异性结合TMPRSS4的人抗体的互补决定区(CDR)和构架区(FR)的人抗体。 在本发明的各种癌细胞中表达的TMPRSS4特异性人抗体可用于诊断癌症,分类疾病,可视化,治疗和预后评价。
-
公开(公告)号:US20110189087A1
公开(公告)日:2011-08-04
申请号:US13124603
申请日:2008-11-10
申请人: Young Woo Park , So-Young Choi , Young-Soon Jang , Ji Hyun Park , Eun-Jung Song , Jung Yu , Myung-Ho Sohn , Jae Won Jeon , Joon-Goo Jung , Sungsub Kim , Myeoung Hee Jang
发明人: Young Woo Park , So-Young Choi , Young-Soon Jang , Ji Hyun Park , Eun-Jung Song , Jung Yu , Myung-Ho Sohn , Jae Won Jeon , Joon-Goo Jung , Sungsub Kim , Myeoung Hee Jang
IPC分类号: A61K51/10 , C07K16/40 , C07H21/00 , A61K39/395 , A61P35/00
CPC分类号: C07K16/40 , A61K2039/505 , C07K2317/21 , C07K2317/52 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C12N9/6424
摘要: The present invention relates to a transmembrane protease, serine (TMPRSS4)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to TMPRSS4. The TMPRSS4-specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.
摘要翻译: 本发明涉及跨膜蛋白酶,丝氨酸(TMPRSS4) - 特异性人抗体,更具体地涉及包含衍生自特异性结合TMPRSS4的人抗体的互补决定区(CDR)和构架区(FR)的人抗体。 在本发明的各种癌细胞中表达的TMPRSS4特异性人抗体可用于诊断癌症,分类疾病,可视化,治疗和预后评价。
-
公开(公告)号:US08236312B2
公开(公告)日:2012-08-07
申请号:US12580959
申请日:2009-10-16
申请人: Young Woo Park , So-Young Choi , Eun-Jung Song , Jung Yu , Myung-Ho Sohn , Jae Won Jeon , Joon-Goo Jung , Myeoung Hee Jang , Sungsub Kim
发明人: Young Woo Park , So-Young Choi , Eun-Jung Song , Jung Yu , Myung-Ho Sohn , Jae Won Jeon , Joon-Goo Jung , Myeoung Hee Jang , Sungsub Kim
IPC分类号: A61K39/395 , C07K16/22 , C12N15/13
CPC分类号: C07K16/22 , C07K2317/21 , C07K2317/622 , C07K2317/76
摘要: The present invention relates to a vascular endothelial growth factor (VEGF)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to VEGF. The VEGF-specific human antibody of the present invention may be used in diagnosis of diseases caused by the VEGF-overexpression, classification of the diseases, visualization, treatment, and prognostic evaluation.
摘要翻译: 本发明涉及血管内皮生长因子(VEGF)特异性人抗体,更具体地涉及包含衍生自特异性结合VEGF的人抗体的互补决定区(CDR)和框架区(FR)的人抗体。 本发明的VEGF特异性人抗体可用于诊断由VEGF过表达,疾病分类,可视化,治疗和预后评估引起的疾病。
-
公开(公告)号:US20100129373A1
公开(公告)日:2010-05-27
申请号:US12580959
申请日:2009-10-16
申请人: Young Woo Park , So-Young Choi , Eun-Jung Song , Jung Yu , Myung-Ho Sohn , Jae Won Jeon , Joon-Goo Jung , Myeoung Hee Jang , Sungsub Kim
发明人: Young Woo Park , So-Young Choi , Eun-Jung Song , Jung Yu , Myung-Ho Sohn , Jae Won Jeon , Joon-Goo Jung , Myeoung Hee Jang , Sungsub Kim
CPC分类号: C07K16/22 , C07K2317/21 , C07K2317/622 , C07K2317/76
摘要: The present invention relates to a vascular endothelial growth factor (VEGF)-specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to VEGF. The VEGF-specific human antibody of the present invention may be used in diagnosis of diseases caused by the VEGF-overexpression, classification of the diseases, visualization, treatment, and prognostic evaluation.
摘要翻译: 本发明涉及血管内皮生长因子(VEGF)特异性人抗体,更具体地涉及包含衍生自特异性结合VEGF的人抗体的互补决定区(CDR)和框架区(FR)的人抗体。 本发明的VEGF特异性人抗体可用于诊断由VEGF过表达,疾病分类,可视化,治疗和预后评估引起的疾病。
-
公开(公告)号:US08197809B2
公开(公告)日:2012-06-12
申请号:US12523516
申请日:2008-11-24
申请人: Young Woo Park , So-Young Choi , Ji Hyun Park , Jung Yu , Eun-Jung Song , Sungsub Kim , Myeoung Hee Jang , Mi-Ju Park , Je-Ho Lee , Jae Ryoung Hwang
发明人: Young Woo Park , So-Young Choi , Ji Hyun Park , Jung Yu , Eun-Jung Song , Sungsub Kim , Myeoung Hee Jang , Mi-Ju Park , Je-Ho Lee , Jae Ryoung Hwang
IPC分类号: C07K16/00 , G01N33/53 , A61K39/395
CPC分类号: C07K16/2896 , C07K2317/21 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要: The present invention relates to a CD9-specific human antibody, more precisely a CD9-specific human antibody composed of human derived CD9-specific complementarity determining region (CDR) and framework region (FR). The human antibody of the present invention recognizes CD9 extracellular loop 2 domain (CD9-ECL2) as an epitope and thereby strongly binding thereto. The human antibody of the present invention also has CD9 antigen neutralizing effect and at the same time inhibiting effect on tumor cell lines. Therefore, it can be effectively used for the prevention and treatment of cancer overexpressing CD9.
摘要翻译: 本发明涉及CD9特异性人抗体,更确切地说,涉及由人衍生的CD9特异性互补决定区(CDR)和框架区(FR)组成的CD9特异性人抗体。 本发明的人抗体识别CD9细胞外环2结构域(CD9-ECL2)作为表位,从而与其强结合。 本发明的人抗体也具有CD9抗原中和作用,同时对肿瘤细胞株具有抑制作用。 因此,它可以有效地用于预防和治疗过度表达CD9的癌细胞。
-
公开(公告)号:US20110195027A1
公开(公告)日:2011-08-11
申请号:US12523516
申请日:2008-11-24
申请人: Young Woo Park , So-Young Choi , Ji Hyun Park , Jung yu , Eun-Jung Song , Sungsub Kim , Myeoung Hee Jang , Mi-Ju Park , Je-Ho Lee , Jae Ryoung Hwang
发明人: Young Woo Park , So-Young Choi , Ji Hyun Park , Jung yu , Eun-Jung Song , Sungsub Kim , Myeoung Hee Jang , Mi-Ju Park , Je-Ho Lee , Jae Ryoung Hwang
IPC分类号: A61K49/06 , C07K16/28 , C07H21/04 , A61K39/395 , A61K49/00 , A61P35/00 , C12N15/63 , C12N5/10 , C12P21/06 , G01N33/574
CPC分类号: C07K16/2896 , C07K2317/21 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要: The present invention relates to a CD9-specific human antibody, more precisely a CD9-specific human antibody composed of human derived CD9-specific complementarity determining region (CDR) and framework region (FR). The human antibody of the present invention recognizes CD9 extracellular loop 2 domain (CD9-ECL2) as an epitope and thereby strongly binding thereto. The human antibody of the present invention also has CD9 antigen neutralizing effect and at the same time inhibiting effect on tumor cell lines. Therefore, it can be effectively used for the prevention and treatment of cancer overexpressing CD9.
摘要翻译: 本发明涉及CD9特异性人抗体,更确切地说,涉及由人衍生的CD9特异性互补决定区(CDR)和框架区(FR)组成的CD9特异性人抗体。 本发明的人抗体识别CD9细胞外环2结构域(CD9-ECL2)作为表位,从而与其强结合。 本发明的人抗体也具有CD9抗原中和作用,同时对肿瘤细胞株具有抑制作用。 因此,它可以有效地用于预防和治疗过度表达CD9的癌细胞。
-
公开(公告)号:US20120039911A1
公开(公告)日:2012-02-16
申请号:US13146876
申请日:2009-01-28
申请人: Young Woo Park , Jae Won Jeon , Joon-Goo Jung , Hye In Choi , Myung-ho Sohn , Ho youn Kim , Mi-La Cho , Young-Soon Jang , Ji-Hun Moon , Ji Hyun Park
发明人: Young Woo Park , Jae Won Jeon , Joon-Goo Jung , Hye In Choi , Myung-ho Sohn , Ho youn Kim , Mi-La Cho , Young-Soon Jang , Ji-Hun Moon , Ji Hyun Park
IPC分类号: A61K39/395 , C07H21/02 , A61K31/713 , A61P29/00 , A61P11/06 , A61P37/08 , A61P1/00 , A61P1/04 , A61P13/12 , A61P31/14 , A61P11/00 , A61P25/00 , A61P25/06 , A61P31/12 , A61P31/04 , A61P31/10 , A61P17/02 , A61P9/10 , A61P19/06 , A61P19/02 , A61P35/00 , A61P1/18 , A61P27/02 , A61P17/00 , C12P21/08 , G01N33/566 , C12Q1/68 , C07K16/28
CPC分类号: A61K31/7105 , G01N33/6893 , G01N2333/70596
摘要: The present invention relates to an anti-inflammatory composition using the antibody specifically binding to CD93 or its soluble fragment, and a diagnostic method and a diagnostic kit for inflammatory disease using CD93 or its soluble fragment specific antibody or aptamer.
摘要翻译: 本发明涉及使用特异性结合CD93或其可溶性片段的抗体的抗炎组合物,以及使用CD93或其可溶性片段特异性抗体或适体的炎性疾病的诊断方法和诊断试剂盒。
-
公开(公告)号:US08993343B2
公开(公告)日:2015-03-31
申请号:US13146876
申请日:2010-01-18
申请人: Young Woo Park , Jae Won Jeon , Joon-Goo Jung , Hye In Choi , Myung-ho Sohn , Ho youn Kim , Mi-La Cho , Young-Soon Jang , Ji-Hun Moon , Ji Hyun Park
发明人: Young Woo Park , Jae Won Jeon , Joon-Goo Jung , Hye In Choi , Myung-ho Sohn , Ho youn Kim , Mi-La Cho , Young-Soon Jang , Ji-Hun Moon , Ji Hyun Park
IPC分类号: G01N33/566 , G01N33/53 , A61K31/7105 , G01N33/68
CPC分类号: A61K31/7105 , G01N33/6893 , G01N2333/70596
摘要: The present invention relates to an anti-inflammatory composition using the antibody specifically binding to CD93 or its soluble fragment, and a diagnostic method and a diagnostic kit for inflammatory disease using CD93 or its soluble fragment specific antibody or aptamer.
摘要翻译: 本发明涉及使用特异性结合CD93或其可溶性片段的抗体的抗炎组合物,以及使用CD93或其可溶性片段特异性抗体或适体的炎性疾病的诊断方法和诊断试剂盒。
-
公开(公告)号:US08778901B2
公开(公告)日:2014-07-15
申请号:US12227923
申请日:2006-11-10
申请人: Young Woo Park , Semi Kim , Kiwon Jo , Ji Hyun Park , Heekyung Jung , Kwang Pyo Lee , So Jeong Park , Young-soon Jang , So-Young Choi , Joon-Goo Jung , Hyo Jeong Hong , Jeong Ho Yoon , Jong-Ho Park
发明人: Young Woo Park , Semi Kim , Kiwon Jo , Ji Hyun Park , Heekyung Jung , Kwang Pyo Lee , So Jeong Park , Young-soon Jang , So-Young Choi , Joon-Goo Jung , Hyo Jeong Hong , Jeong Ho Yoon , Jong-Ho Park
IPC分类号: A61K48/00
CPC分类号: A61K31/7084 , C12N15/1137 , C12N2310/14
摘要: The present invention relates to an anticancer agent containing a TMPRSS4 (transmembrane protease, serine 4) inhibitor as an effective ingredient, more precisely an anticancer agent containing an inhibitor of TMPRSS4 activity as an effective ingredient. The anticancer agent of the present invention can be used effectively for the treatment of cancer by inhibiting TMPRSS4 expression in cancer cells and thereby inhibiting cancer cell invasion and cancer cell growth.
摘要翻译: 本发明涉及含有TMPRSS4(跨膜蛋白酶,丝氨酸4)抑制剂作为有效成分的抗癌剂,更准确地说,涉及含有TMPRSS4活性抑制剂作为有效成分的抗癌剂。 本发明的抗癌剂通过抑制癌细胞中的TMPRSS4表达,从而抑制癌细胞侵袭和癌细胞生长,可以有效地用于治疗癌症。
-
公开(公告)号:US20110318361A1
公开(公告)日:2011-12-29
申请号:US12227923
申请日:2006-11-10
申请人: Young Woo Park , Semi Kim , Kiwon Jo , Ji Hyun Park , Heekyung Jung , Kwang Pyo Lee , So Jeong Park , Young-soon Jang , So-Young Choi , Joon-Goo Jung , Hyo Jeong Hong , Jeong Ho Yoon , Jong-Ho Park
发明人: Young Woo Park , Semi Kim , Kiwon Jo , Ji Hyun Park , Heekyung Jung , Kwang Pyo Lee , So Jeong Park , Young-soon Jang , So-Young Choi , Joon-Goo Jung , Hyo Jeong Hong , Jeong Ho Yoon , Jong-Ho Park
IPC分类号: A61K39/395 , C07K16/40 , C12N15/09 , C12N15/63 , A61P35/00 , A61K31/713 , C12Q1/37 , C12Q1/68 , G01N33/53 , C07H21/02 , C12N5/10
CPC分类号: A61K31/7084 , C12N15/1137 , C12N2310/14
摘要: The present invention relates to an anticancer agent containing a TMPRSS4 (transmembrane protease, serine 4) inhibitor as an effective ingredient, more precisely an anticancer agent containing an inhibitor of TMPRSS4 activity as an effective ingredient. The anticancer agent of the present invention can be used effectively for the treatment of cancer by inhibiting TMPRSS4 expression in cancer cells and thereby inhibiting cancer cell invasion and cancer cell growth.
摘要翻译: 本发明涉及含有TMPRSS4(跨膜蛋白酶,丝氨酸4)抑制剂作为有效成分的抗癌剂,更准确地说,涉及含有TMPRSS4活性抑制剂作为有效成分的抗癌剂。 本发明的抗癌剂通过抑制癌细胞中的TMPRSS4表达,从而抑制癌细胞侵袭和癌细胞生长,可以有效地用于治疗癌症。
-
-
-
-
-
-
-
-
-